晚期非小细胞肺癌特殊人群免疫治疗临床研究进展  

Clinical Progress of Immunotherapy in Special Population with Advanced Non-Small Cell Lung Cancer

作　　者：刘铮 田鹏 李东 Liu Zheng;Tian Peng;Li Dong(Department of Oncology,the General Hospital of Western Theater Command PLA,Chengdu 610083,Sichuan,China)

机构地区：[1]中国人民解放军西部战区总医院肿瘤诊治中心,成都610036

出　　处：《肿瘤预防与治疗》2022年第3期285-291,共7页Journal of Cancer Control And Treatment

基　　金：国家自然科学基金(编号:81101634);四川省科技厅计划项目(编号:2015FZ0073)。

摘　　要：相较于传统放化疗,免疫检查点抑制剂(immune checkpoint inhibitor,ICI)的单药或联合治疗使晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者5年生存率显著提高。但由于严苛的入组标准,绝大多数前瞻性临床研究并未纳入晚期NSCLC患者中多种不同类型的特殊人群,如免疫功能受损(慢性病毒感染和免疫抑制剂使用)、免疫系统失调(自身免疫疾病和移植)、合并严重疾病(器官功能障碍与中枢神经系统转移)、高危(孕妇、高ECOG/PS评分以及高龄)患者。本文旨在系统回顾与梳理ICI药物在这类特殊人群中的安全性和疗效数据,为临床上更好地应用ICI药物提供参考。Compared to traditional radiotherapy and chemotherapy,the solely use of immune checkpoint inhibitor(ICI)or as a complement has significantly improved the five-year survival rate of advanced non-small cell lung cancer patients.Due to its rigorous entry criteria,special populations,such as patients with impaired immune functions(those with chronic viral infections,immunosuppressant users),patients with immune system disorders(those with autoimmune diseases,those undergoing transplantation),patients with severe complications(those with organ dysfunctions,those with central nervous system metastasis)and high-risk patients(pregnant women,those with high ECOG/PS scores,and the elderly),were commonly excluded from clinical research.This article systematically reviews the effects of ICIs in special populations,providing promising hints for clinical treatment.

关 键 词：晚期非小细胞肺癌 免疫治疗 特殊人群 

分 类 号：R734.2[医药卫生—肿瘤] R730.51[医药卫生—临床医学]